The CHANCE001 trial reported that TACE combined with PD-(L)1 inhibitors and molecular targeted therapies significantly improved PFS, OS, and ORR in predominantly advanced HCC patients compared to TACE alone (12). This evidence concerns the gene CD274 and hepatocellular carcinoma.